Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment

Reproductive Toxicology

Volumn 51, Issue , 2015, Pages 90-105

  Destexhe, E ^a   Stannard, D ^b   Wilby, O K ^b   Grosdidier, E ^c   Baudson, N ^a   Forster, R ^c   Gerard C M ^a   Garcon N ^d   Segal, L ^a  

^a GSK   (Belgium)

^b HUNTINGDON LIFE SCIENCES   (United Kingdom)

^c SOLVO BIOTECHNOLOGY   (Hungary)

^d BIOASTER   (France)

Author keywords

Cancer immunotherapy; Immunostimulant; Monkey; Rat; Reproductive toxicity

Indexed keywords

CANCER VACCINE; IMMUNOSTIMULATING AGENT; MELANOMA ANTIGEN 3; ANTIBODY; MAGEA3 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EMBRYO; FEMALE; FERTILITY; FOOD INTAKE; HISTOPATHOLOGY; LACTATION; MACACA FASCICULARIS; MALE; MALE FERTILITY; MATING; MORTALITY; NONHUMAN; RAT; REPRODUCTION; SEROLOGY; SURVIVAL; TOXICITY TESTING; ANIMAL; BLOOD; DRUG EFFECTS; EMBRYO DEVELOPMENT; FETUS DEVELOPMENT; IMMUNOLOGY; IMMUNOTHERAPY;

MACACA FASCICULARIS; RATTUS;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CANCER VACCINES; EMBRYONIC DEVELOPMENT; FEMALE; FERTILITY; FETAL DEVELOPMENT; IMMUNOTHERAPY; MACACA FASCICULARIS; MALE; NEOPLASM PROTEINS; RATS; REPRODUCTION;

EID: 84922378414     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.12.009     Document Type: Article

References (53)

1. Aldrich J.F., Lowe D.B., Shearer M.H., Winn R.E., Jumper C.A., Kennedy R.C. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol 2010, 697158. 10.1155/2010/697158.
2. Andersen M.H., Junker N., Ellebaek E., Svane I.M., Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol 2010, 237623. 10.1155/2010/237623.
3. Bilusic M., Gulley J.L. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 2012, 61:109-117. 10.1007/s00262-011-1141-0.
4. Weir G.M.L.R., Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers 2011, 3:3114-3142. 10.3390/cancers3033114.
5. Dimberu P.M., Leonhardt R.M. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med 2011, 84:371-380.
6. Lippert T.H., Ruoff H.J., Volm M. Current status of methods to assess cancer drug resistance. Int J Med Sci 2011, 8:245-253.
7. Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013, 85:1219-1226. 10.1016/j.bcp.2013.02.017.
8. Canil C., Hotte S., Mayhew L.A., Waldron T.S., Winquist E. Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J 2010, 4:201-208.
9. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294.
10. Petrella T., Quirt I., Verma S., Haynes A.E., Charette M., Bak K., et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007, 33:484-496. 10.1016/j.ctrv.2007.04.003.
11. Buonaguro L., Petrizzo A., Tornesello M.L., Buonaguro F.M. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011, 18:23-34. 10.1128/CVI.00286-10.
12. Palena C., Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010, 380697. 10.1155/2010/380697.
13. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003, 21:807-839. 10.1146/annurev.immunol.21.120601.141135.
14. Garcon N., Heppner D.G., Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003, 2:231-238. 10.1586/14760584.2.2.231.
15. Brasseur F., Rimoldi D., Lienard D., Lethe B., Carrel S., Arienti F., et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63:375-380.
16. Sienel W., Varwerk C., Linder A., Kaiser D., Teschner M., Delire M., et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004, 25:131-134. 10.1016/j.ejcts.2003.09.015.
17. Van den Eynde B.J., van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693. 10.1016/S0952-7915(97)80050-7.
18. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De P.E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647. 10.1126/science.1840703.
19. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403. 10.1200/JCO.2012.43.7103.
20. Hudolin T., Kastelan Z., Derezic D., Basic-Jukic N., Cesare Spagnoli G., Juretic A., et al. Expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 cancer-testis antigens in fetal testis. Acta Dermatovener Croat 2009, 17:103-107.
21. Jungbluth A.A., Ely S., DiLiberto M., Niesvizky R., Williamson B., Frosina D., et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005, 106:167-174. 10.1182/blood-2004-12-4931.
22. Nelson P.T., Zhang P.J., Spagnoli G.C., Tomaszewski J.E., Pasha T.L., Frosina D., et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007, 7:1.
23. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32. 10.1034/j.1600-065X.2002.18803.x.
24. Zarour H.M., DeLeo A., Finn O.J., Storkus W.J. Cancer-testis (CT) antigens 2003, BC Decker Inc. 6th ed.
25. Vergati M., Intrivici C., Huen N.Y., Schlom J., Tsang K.Y. Strategies for cancer vaccine development. J Biomed Biotechnol 2010, 10.1155/2010/596432.
26. Kruit W.H., Suciu S., Dreno B., Mortier L., Robert C., Chiarion-Sileni V., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013, 31:2388-2395. 10.1200/JCO.2012.44.3762.
27. Mead G. The effects of cancer treatment on reproductive functions. Clin Med 2007, 7:544-545. 10.7861/clinmedicine.7-6-544.
28. Jeruss J.S., Woodruff T.K. Preservation of fertility in patients with cancer. N Engl J Med 2009, 360:902-911. 10.1056/NEJMra0801454.
29. Lee S.J., Schover L.R., Partridge A.H., Patrizio P., Wallace W.H., Hagerty K., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24:2917-2931. 10.1200/JCO.2006.06.5888.
30. Levine J. Gonadotoxicity of cancer therapies in pediatric and reproductive-age females. Oncofertility medical practice: clinical issues and implementation 2012, Springer Science+Business Media, New York, [Chapter 1]. C. Gracia, T.K. Woodruff (Eds.).
31. European Medicines Agency Guidance for industry: considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications 2006.
32. European Medicines Agency. ICH Topic S5 (R2): detection of toxicity to reproduction for medicinal products and toxicity to male fertility. Note for guidance on the detection of toxicity to reproduction for medicinal products and toxicity to male fertility (CPMP/ICH/386/95).
33. European Medicines Agency Note for guidance on preclinical pharmacological and toxicological testing of vaccines 1997.
34. World Health Organization WHO guidelines on nonclinical evaluation of vaccines 2003.
35. BLAST.
36. Destexhe E., Grosdidier E., Baudson N., Forster R., Gerard C., Garcon N., et al. Nonclinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and Cynomolgus monkeys. J Appl Toxicol 2014, 10.1002/jat.3025.
37. The UK GLP Regulations Statutory instruments 1999 No. 3106: health and safety 1999.
38. Organisation for Economic Co-operation Development OECD series on principles of good laboratory practice and compliance monitoring 1997, OECD Principles on Good Laboratory Practice (as revised in 1997).
39. The European Parliament, The Council of the European Union Directive 2004/10/EC of the European parliament and of the council of 11 February 2004. Off J Eur Union 2004, 50-59.
40. Solidarité Mdledl ARRÊTÉ DU 14 MARS 2000 relatif aux bonnes pratiques de laboratoire 2000.
41. Vantomme V., Dantinne C., Amrani N., Permanne P., Gheysen D., Bruck C., et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004, 27:124-135.
42. Segal L., Wilby O.K., Willoughby C.R., Veenstra S., Deschamps M. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 2011, 31:111-120. 10.1016/j.reprotox.2010.09.001.
43. Fischer R.A. Statistical methods for research workers 1973, Hafner Publishing Company, New York, USA. 14th ed.
44. Bartlett M.S. Properties of sufficiency and statistical tests. Proc R Soc Lond 1937, 160:268-282.
45. Wilcoxon F. Individual comparisons by ranking methods. Biom Bull 1945, 1:80-83.
46. Lipsitz S.R.L.N., Harrington D.P. Generalised estimating equations for correlated binary data: using the odds ratio as a measure of association. Biometrika 1991, 78:153-160. 10.1093/biomet/78.1.153.
47. Angervall L., Carlstrom E. Theoretical criteria for the use of relative organ weights and similar ratios in biology. J Theor Biol 1963, 4:254-259.
48. Czoty P.W., Gould R.W., Nader M.A. Relationship between social rank and cortisol and testosterone concentrations in male cynomolgus monkeys (Macaca fascicularis). J Neuroendocrinol 2009, 21:68-76. 10.1111/j.1365-2826.2008.01800.x.
49. Shandilya L., Clarkson T.B., Adams M.R., Lewis J.C. Effects of gossypol on reproductive and endocrine functions of male cynomolgus monkeys (Macaca fascicularis). Biol Reprod 1982, 27:241-252. 10.1095/biolreprod27.1.241.
50. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021. 10.1111/j.1349-7006.2009.01303.x.
51. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001, 61:5544-5551.
52. Gerard C., Baudson N., Ory T., Louahed J. Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLOS ONE 2014, 9:e94883. 10.1371/journal.pone.0094883.
53. Lin H., Mosmann T.R., Guilbert L., Tuntipopipat S., Wegmann T.G. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993, 151:4562-4573.